finance.yahoo.com ·
catalyst pharmaceuticals buyout firdapse patents 071027283
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAcquisition of Catalyst Pharmaceuticals by Angelini Pharma at $4.1 billion. The deal secures Catalyst's FIRDAPSE (a drug for Lambert-Eaton myasthenic syndrome) patent protection until 2035, ensuring monopoly pricing power. The channel is regulatory (patent settlement) and corporate control change. Impact is single-company/supply-chain-specific: Catalyst shareholders receive premium, Angelini gains exclusive U.S. rights to FIRDAPSE. No broader sector or commodity impact.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Catalyst Pharmaceuticals to be acquired by Angelini Pharma for $4.1 billion.
- Deal has unanimous board approval, expected to close in Q3 pending approvals.
- All FIRDAPSE patent litigation resolved, securing U.S. market exclusivity until at least January 2035.
- Catalyst stock closed at $31.17, up 10.8% over past week and 24.7% over past month.
FIRDAPSE's market impact is flat in the mid-term (1-4 weeks) with low magnitude. Increased M&A speculation may affect sector valuations.
Sign in to see all sector verdicts, full thesis and counter-argument debate.